Tumor Specific Imaging Using Tc-99m and Ga-68 Labeled Radiopharmaceuticals

David J. Yang, Ali Azhdarinia and E. Edmund Kim

*Department of Nuclear Medicine, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA

Abstract: Improvement of scintigraphic tumor imaging is extensively determined by the development of more tumor specific radiopharmaceuticals. Thus, to improve the differential diagnosis, prognosis, planning and monitoring of cancer treatment, several functional pharmaceuticals have been developed. Application of molecular targets for cancer imaging, therapy and prevention using generator-produced isotopes are the major focus of ongoing research projects. Radionuclide imaging modalities (positron emission tomography, PET; single photon emission computed tomography, SPECT) are diagnostic cross-sectional imaging techniques that map the location and concentration of radionuclide-labeled radiotracers. $^{99m}$Tc- and $^{68}$Ga-labeled agents using ethylenedicycisteine (EC) as a chelator were synthesized and their potential uses to assess tumor targets were evaluated. $^{99m}$Tc ($t_{1/2}=6$ hr, 140 keV) is used for SPECT and $^{68}$Ga ($t_{1/2}=68$ min, 511 keV) is for PET. Molecular targets labeled with Tc-99m and Ga-68 can be utilized for prediction of therapeutic response, monitoring tumor response to treatment and differential diagnosis. Molecular targets for oncological research in (1) cell apoptosis, (2) gene and nucleic acid-based approach, (3) angiogenesis (4) tumor hypoxia, and (5) metabolic imaging are discussed. Numerous imaging ligands in these categories have been developed and evaluated in animals and humans. Molecular targets were imaged and their potential to redirect optimal cancer diagnosis and therapeutics were demonstrated.

Keywords: Ethylenedicycisteine, cancer, imaging, technetium-99m, gallium-68.

INTRODUCTION

Assessment of the effectiveness of cancer therapy (e.g. volumetric and morphological changes) is measured by CT and MRI. In addition to these imaging modalities, the treatment endpoints rely almost exclusively on the analysis of biopsies by molecular and histopathological methods. These methods provide a microscopic picture of the general heterogeneous process. Therefore, to assess clinical endpoints adequately, a specific target assessment marker is needed that would allow precise measurement of tumor targets on a whole-body image upon administration of a functional agent. These mechanism-based agents provide image-guided therapy which may discontinue ineffective treatment in an earlier phase and switch to a more efficient treatment that would be beneficial to patients early on in the course of treatment.

PET and SPECT use radiotracers to image, map and measure target site activities (e.g. angiogenesis, metabolism, apoptosis and proliferation) and they are considered as molecular imaging modalities [1-3].

Reliable molecular imaging assays that assess (1) cellular targets at low cost (2) treatment response more rapidly, (3) differential diagnosis, (4) the prediction of therapeutic response, and (5) better radiation dosimetry for internal radiotherapy would be very valuable. Here, we report a series of tumor-specific agents that may provide potential applications in differential diagnosis and prediction of early treatment response.

SELECTION OF ISOTOPES AND CHEMISTRY CHELATORS FOR IMAGING

To develop novel or clinically used tracers, two types of chemistries are frequently used in the preparation of radiotracers: covalent and ionic. In covalent chemistry, either displacement or addition reactions are used to place an isotope in the molecule. The labeled product provides minimal structural alteration, however, the procedure may be lengthy, tedious, with low yield, and costly. Isotopes commonly used in covalent chemistry include $^{18}$F, $^{111}$I, $^{89}$Br, $^{7}$Br and $^{11}$C. In complex chemistry, a chelator is required to trap metal isotopes. This type of chemistry is simple and with high yield. The isotopes may be obtained from generators. Though complex chemistry is attractive, the chemical properties may be altered due to the addition of a chelator.

Among all SPECT radioisotopes, $^{99m}$Tc has been preferred to label radiopharmaceuticals due to favorable low energy (140 keV), inexpensive isotope cost ($0.21/mCi) and easy chemistry. Several $^{99m}$Tc-labeling chelators have been reported such as $N_4$ (e.g. Cyclam-14, DOTA), $N_2S_2$ (e.g. MAG-3), $N_2S_2$ (e.g. ECD), $N_3$S$_3$ (e.g. sulfur colloid), diethylenetriamine pentaacetic acid (DTPA), $O_3$S$_2$ (e.g. DMSA), and hydrazinonicotinamide (HYNIC) [4-10]. Among these chelators, DTPA forms less stable complexes with $^{99m}$Tc. $^{99m}$Tc-HYNIC has been shown to be useful in imaging, but labeling HYNIC with $^{99m}$Tc requires two chem-
icals, thiphenylphosphine and tricine, which are inconvenient for the kit preparation. The nitrogen and sulfur combination has been shown to be a stable chelator for $^{99m}$Tc-bis-aminooxothiol tetradentate ligands, also called diaminodithiol compounds, and are known to form very stable Tc(V)O-complexes on the basis of efficient binding of the oxotechnetium group to thiosulfur and two amine nitrogen atoms. L,L-ethylenedicysteine (EC) is the most successful example of N$_2$S$_2$ chelates [11]. EC can be labeled with both $^{68}$Ga and $^{99m}$Tc efficiently with high radiochemical purity and the preparation remains stable for several hours [12-22].

In addition to assessing molecular targets, $^{99m}$Tc might be useful in planning internal targeted radionuclide therapy with $^{188}$Re-labeled agents. $^{188}$Re has good characteristics for imaging and for potential therapeutic use because of its high $\beta$ energy (2.1 MeV), short physical half-life (16.9 hr) and 155 keV $\gamma$-ray emission for dosimetric and imaging purposes. The short physical half-life of $^{188}$Re allows for higher doses compared with long-lived radionuclides. Furthermore, the short half-life reduces the problems of radioactive waste handling and storage. In particular, $^{188}$Re is available from an in-house generator system similar to a $^{99m}$Tc generator. $^{188}$Re can be obtained from a $^{188}$W/$^{188}$Re generator, which makes it very convenient for clinical use. Both $^{99m}$Tc- and $^{188}$Re emit gamma rays, so the dosimetry generated based on $^{99m}$Tc images is expected to be more accurate than that produced using the current standard radioisotope, Y-90.

PET radiosynthesis must be rapid because the radioisotope will decay during lengthy chemical synthesis and higher risk of radiation exposure may occur during radiosynthesis. Cyclotron-based tracers are constrained by the availability of local cyclotron and its high cost. The Food and Drug Administration (FDA) permits radiopharmaceuticals production in central commercial facilities under well-controlled conditions and distribution to local clinics where they are administered. Similarly, radionuclide generator systems that can be produced in a well-controlled facility are embraced by current FDA procedures and have a long history of successful clinical application. A generator uses a parent-daughter nuclide pair wherein a relatively long-lived parent isotope decays to a short-lived daughter isotope that is used for imaging. The parent isotope, which is produced at a cyclotron facility, can be shipped to a clinical site and from which the daughter isotope may be eluted on site for clinical use. In our case, $^{68}$Ga-based PET agents possess significant commercial potential because the isotope can be produced from a $^{68}$Ge generator (275-day half-life) on site and serve as a convenient alternative to cyclotron-based PET isotopes, such as $^{18}$F or $^{23}$I. $^{68}$Ga has a high positron emitting quantity (89% of its total decay), therefore the main consideration is its spatial resolution, which depends on the positron range (energy), the non-colinearity of annihilating photons, intrinsic properties, size and geometry of the detector and the selection of the reconstruction algorithm. Aspects of the detector design, physical properties and their influence on system spatial resolution have been extensively addressed by many authors, leading to a continuous optimization of hardware. Although the maximum positron energy of $^{68}$Ga (max=1.90 MeV, mean=0.89 MeV) is higher than that of $^{18}$F (max=0.63 MeV, mean=0.25 MeV), a study using Monte Carlo analysis on spatial resolution revealed that under the assumption of 3 mm spatial resolution of PET detectors, the conventional full width at half maximum (FWHM) of $^{18}$F and $^{68}$Ga are indistinguishable in soft tissue (3.01 mm vs. 3.09 mm) [23,24]. It implies that with the spatial resolution at 5 to 7 mm of current clinical scanners, the imaging quality using $^{68}$Ga-based tracers can be as good as that of $^{18}$F-based agents and have stimulated others to investigate potential $^{68}$Ga-based imaging agents [25-27]. In this report, a series of EC-agents in oncology target assessment are reviewed.

**ASSESSMENT OF APOPTOSIS**

The importance of apoptosis in determining chemotherapy response remains unclear. Some authors have suggested that apoptosis may be the most critical determinant of a tumor’s sensitivity or resistance to chemotherapy [28]. However, investigations that have studied the importance of apoptosis in human solid tumors have been sparse. Studies of cervical cancer have found the baseline apoptotic index (AI) of the malignant cells to be prognostic of clinical response to chemotherapy and overall survival [29,30]. In addition, the response of cervical cancer to cisplatin has been found to correlate with the level of therapy-induced apoptosis [29]. The importance of the baseline AI in breast cancer has never been investigated, and determining the importance of therapy-induced apoptosis in solid tumors currently remains a relatively unexplored area of clinical research.

One possible reason that there is little information concerning therapy-induced apoptosis in human tumors is that the histological evidence of apoptosis occurs within a brief period immediately after treatment. *In vivo* work has revealed that apoptosis of breast cancer cells rapidly increases to a peak after chemotherapy, and then rapidly declines to baseline levels [31-34]. In the murine mammary carcinoma, the time of greatest therapy-induced apoptosis was 24-40 hours after initiation of chemotherapy. Whether this is the optimal time in human breast cancer patients is currently unknown. Buchholz et al. [35] investigated whether changes in tumor cell apoptosis and Bcl-2 expression immediately after chemotherapy correlated with response to breast cancer treatment. Apoptosis levels were quantified by use of a fluorescent terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphat nick end-labeling (TUNEL) stain, and Bcl-2 and Bax were measured by semi-quantitative immunohistochemical assays. The apoptosis level at 48 hours was significantly higher in the tumors with pathologically complete response or < 1 cm of residual disease (median, 22%; range, 6%-51%) than in the tumors with > 1 cm residual disease (median, 7%; range, 1%-36%). A decrease in Bcl-2 expression after chemotherapy y relative to the expression from the pretreatment sample also correlated with disease response. Furthermore, Symmans et al. [36] demonstrated that AI was an accurate method to detect paclitaxel-induced apoptosis in women with primary breast cancer (PBC) receiving induction chemotherapy (IC). The initial grade of apoptotic response inversely related with the amount of residual disease at surgery. These data suggested that apoptosis may play an important role in determining breast cancer response to...
chemotherapy and that the level of treatment-induced apoptosis may have some value as a predictive marker. Recently, an enzyme linked immunosorbent assay (ELISA) has been developed to detect the caspase cleavage fragment of CK18 (M30-antigen) [37]. High M30-antigen levels have been demonstrated in patients with metastatic breast cancer compared to healthy controls.

We have formulated $^{99m}$Tc-EC-annexin V for assessment of apoptosis in animal models [13]. When compared to $^{99m}$Tc-HYNIC-annexin V in rat models, the kidneys had the highest concentration of radioactivity (%injected dose/gram) at 10min-180 min after intravenous injection of $^{99m}$Tc-HYNIC-annexin V (9.5-17) and $^{99m}$Tc-EC-annexin V (4.9-6.9). $^{99m}$Tc-HYNIC-annexin V had faster blood clearance than $^{99m}$Tc-EC-annexin V (t1/2=15 min vs. 100min). Both agents showed similar uptake in liver and spleen and poor brain uptake [38]. Pharmacokinetic studies were conducted using $^{99m}$Tc-EC-annexin V in 10 breast cancer patients. The protocol was approved by the University of Texas M.D. Anderson Cancer Center Institutional Review Board (ID-02-732). Between December 2003 and February 2004, ten patients with untreated PBC (stage II-III) were enrolled in this prospective study. After a signed informed consent, they received a single intravenous injection of 25-29 mCi of $^{99m}$Tc-EC-annexin V. Subsequently, whole body planar images using a dual-headed gamma camera were obtained at 0.5, 2-4, 18-24 hour after injection. SPECT images of the chest were also obtained 3 hours after injection. Computer outlined regions of interest (ROI) (counts per pixel) were used to determine tumor-to-background count density ratios (T/N). The ratios were used to compare dynamic tumor uptake pre- and post-treatment. Errors in the use of image ROIs as standards to correspond to anatomically relevant features have been described and found tolerable. Five of these patients received a dose of induction therapy 16 hours before the last imaging session. The induction therapy consisted of chemotherapy (paclitaxel, 2 patients; fluorouracil, doxorubicin, cyclophosphamide, FAC, 1 patient) and bcl-2 antisense oligonucleotide (Genasense™, 2 patients). In all cases, there was detectable $^{99m}$Tc-EC-annexin V uptake that corresponded to the area of palpable invasive disease. The selected whole body image is shown in (Fig. 1). The median baseline T/N was 2.11 (range 1.32-3.30). In those patients receiving IC, the mean T/N ratio was 2.57 (range 2.05-3.30, n=5) which was higher than those patients without IC (mean 1.53, range 1.35-1.73, n=4). There was a trend such that a high T/N had a better response. Based upon quantification of the serial whole body images from the clinical studies to generate estimated residence times, dosimetry of $^{99m}$Tc-EC-annexin V was estimated using MIRDose 3.1. Similar to our animal studies, whole body, blood-forming organ and gonad absorbed dose estimates for the proposed single dosage of 25-29 mCi were less than the limits of 3 rem annual and 5 rem total, and those to other organs less than the limits of 5 rem annual and 15 rem total (Table 1). The magnitude of the radiation-absorbed doses was less than those predicted based on animal doses [13]. These early data suggest that assessment of apoptosis by $^{99m}$Tc-EC-annexin V could be useful to evaluate the baseline level of apoptosis, predict the efficacy of therapy based on the detection of treatment-related apoptosis and possibly predict disease progression and prognosis. Furthermore, it appears to correlate with biological markers of proliferation, suggesting a correlation with the occurrence of spontaneous apoptosis.

### $^{99m}$Tc-EC-Annexin V Clinical Images

**Whole-Body**

(2.5 h)

**SPECT**

- Transverse
- Sagittal
- Coronal

*Fig. (1).* A coronal whole body image (left) of a patient who received $^{99m}$Tc-EC-annexin V (25 mCi, i.v., 3 hours) showed that the tumor in the left breast could be well visualized.
ASSESSMENT OF GENE AND NUCLEIC ACID-BASED TARGETS

Assessment of tumor cell proliferation by PET and SPECT could be helpful in the evaluation of tumor growth potential, the degree of malignancy and could provide an early assessment of treatment response. Several efforts have been made to assess tumor proliferative activity. It has been reported that 2'-fluorodeoxyglucose ([18F]FDG) uptake is an indicator of tumor proliferative activity [39]. Higashi et al. have shown that [18F]FDG uptake is strongly related to the number of viable cells [40]. Another approach was to use a radiolabeled amino acid as a tumor cell proliferative marker [41,42]. However, the structures of these agents are not limited to purine or pyrimidine-based, which are essential building blocks of DNA. Although several radiolabeled pyrimidine and purine have been developed, they were used as probes for imaging herpes virus type one thymidine kinase (HSV1-tk) expression and other reporter genes. For example, pyrimidine nucleoside [43] and other [18F]-labeled acycloguanosine analogs [44-48] have been developed as reporter substrates for imaging wild-type and mutant HSV1-tk expression. The difficulty with these probes is that HSV1-tk enzyme expression depends on HSV1-tk gene transduction with adenoviral vectors. The level of HSV1-tk enzyme expression is likely to be altered in different transduced cells and tissue; thus, the application of HSV1-tk probe is limited.

To overcome HSV1-tk enzyme expression, it would be desired to develop a novel tracer to assess efficacy of tumor therapy by measuring proliferative activity. Synthesis and biological activity of labeled thymidine or uridine, which were incorporated into DNA/RNA, have been reported [49-51]. However, either the complex chemistry, shorter half-life of radioisotope, or stability of the agent was involved which limited their practical uses. We previously have reported that [18F]-labeled adenosine, a purine analogue, could measure proliferative activity by PET [52]. Other pyrimidine and purine nucleosides/nucleotides which were incorporated into DNA/RNA have been reported [53-57]. In particular, 3'-deoxy-3'-[18F]-fluorothymidine ([18F]-FLT) is a new tracer which images cellular proliferation by entering the salvage pathway of DNA synthesis. However, DNA incorporation rate of FLT is low and chemical stability is complex [53,54]. In order to enhance biological activity and increase chemical or metabolic stability, fluorine substitution at the C2' position of the sugar moiety (arabino configuration) has been widely investigated in drug research [55-58]. Again, the chemistry is complex and the yield is low. To continuously explore other purine-based analogue using chelation radiochemistry, we then synthesized a guanine analogue using EC as a chelator. 99mTc- and 68Ga-ethylenedicysteine-guanine (EC-Guan) were formulated for evaluation of cell proliferation. The synthetic scheme is shown in (Fig. 2). Both agents were able to differentiate inflammation versus tumors (Figs. 3 and 4). In vitro cell confluence, cell cycle analysis, cellular uptake and in vivo imaging studies [59] suggest that 99mTc- and 68Ga-EC-Guan may be useful as tumor proliferation imaging agents.

ASSESSMENT OF ANGIOGENESIS

Angiogenesis, the proliferation of endothelial and smooth muscle cells to form new blood vessels, is an essential component of the metastatic pathway. These vessels provide the principal route by which tumor cells exit the primary tumor site and enter the circulation. For many tumors, the vascular density can provide a prognostic indicator of metastatic potential or survival, with highly vascularized tumors having a higher incidence of metastasis than poorly vascularized tumors [60,61]. There are four types of antiangiogenic therapy agents [62-65]. They are (1) antibodies, such as anti-integrins (Vitaxin), anti-EGFR (C225), anti-VEGF monoclonal antibody, anti-endoglin glycoprotein (anti-TGFβ); (2) protein fragments, such as plasminogen and collagen (endostatin); (3) modulation of FGF (interferons), and (4) synthetic small molecules, such as...
protease inhibitors, urokinase inhibitors, cyclooxygenase inhibitors and tyrosine kinase inhibitors. These new anti-angiogenic agents represent some of the more promising new approaches to anticancer therapy.

Though several agents were labeled with EC, the target assessment is not the same. Thus, labeled EC was used as a control for each agent itself comparison. $^{99m}$Tc-EC-endostatin was synthesized and studied for its potential as a noninvasive imaging technique for the evaluation and measurement of tumor response to anti-angiogenic therapy. *In vitro* cell viability and TUNEL assays indicated no marked difference between EC-endostatin and endostatin. Cellular uptake assay suggests that endostatin binds to an endostatin receptor. Biodistribution of $^{99m}$Tc-EC-endostatin in tumor-bearing rats showed increased tumor-to-tissue count density ratios as a function of time. Tumor uptake (%ID/g) of $^{99m}$Tc-EC-endostatin was 0.2-0.5. Planar images confirmed that the tumors could be visualized clearly with $^{99m}$Tc-EC rats, there were no significant accumulation in tumor and inflammation. The data was acquired at 500,000 counts.

![Synthesis of EC-Guanine.](image)

**Fig. (2).** Synthesis of EC-Guanine.

**Comparison of $^{99m}$Tc-EC and $^{99m}$Tc-EC-Guanine Imaging in Tumor and Inflammation bearing rats**

![Planar scintigraphy images](image)

**Fig. (3).** Breast tumor (right leg) and inflammation (left leg, by turpentine, i.m.) bearing rats were administered with $^{99m}$Tc-EC-Guanine and $^{99m}$Tc-EC (control) (300 µCi/rat, i.v.). Planar scintigraphy of $^{99m}$Tc-EC-Guanine showed that tumor has more uptake than inflammation at 2 hrs post-injection. In $^{99m}$Tc-EC rats, there were no significant accumulation in tumor and inflammation. The data was acquired at 500,000 counts.

$^{99m}$Tc-EC could also be used to assess treatment response. There was a correlation between tumor uptake and angiogenic target expression. Our results indicate that it may be feasible to use $^{99m}$Tc-EC-endostatin to assess efficiency of anti-angiogenesis therapy [14].
Cyclooxygenase-2 (COX-2) plays an important role in angiogenesis and cancer progression [66]. Since many tumor cells exhibit the COX-2 expression, functional imaging of COX-2 expression using Celebrex (CBX, a COX-2 inhibitor) may provide not only a non-invasive, reproducible, quantifiable alternative to biopsies, but it also greatly complements pharmacokinetic studies by correlating clinical responses with biological effects. Moreover, molecular endpoints of anti-COX-2 therapy could also be assessed effectively. We have developed $^{99m}$Tc-EC-Celecoxib (EC-CBX) for measurement of COX-2 expression in tumor bearing animal models. We conclude that $^{99m}$Tc-EC-CBX may be useful to assess tumor COX-2 expression [19]. This may be useful in the future for selecting patients for treatment with anti-COX-2 agents.

Epidermal Growth Factor Receptor (EGFR) plays an important role in cell division and cancer progression, as well as angiogenesis and metastasis. Since many tumor cells express EGFR on their surface, functional imaging of EGFR provides not only a non-invasive, reproducible, quantifiable alternative to biopsies, but it also greatly complements pharmacokinetic studies by correlating clinical responses with biological effects [67,68]. Moreover, molecular endpoints of anti-EGFR therapy could be assessed effectively. C225 is a chimeric monoclonal antibody that targets the human extracellular EGFR and inhibits the growth of EGFR-expressing tumor cells. Also, it has been demonstrated that C225, in combination with chemotherapeutic drugs or radiotherapy, is effective in eradicating well-established tumors in nude mice. We have developed $^{99m}$Tc-EC-C225 and imaged EGFR-positive tumor bearing animal models. The preliminary feasibility of imaging patients with head and neck carcinomas was also evaluated. Our findings indicate that $^{99m}$Tc-EC-C225 is useful to assess tumor EGFR expression [15]. This may be useful in the future for selecting patients for treatment with C225.

ASSESSMENT OF TUMOR HYPOXIA

It is well established in experimental and clinical studies that most tumors have a considerable proportion of hypoxic cells. Hypoxic tumors are known to be resistant to traditional radio- and chemotherapy, which results in higher local recurrence rates. Hypoxia also induces angiogenesis and adds to the invasive and metastatic potential of cancer cells and further compromises therapeutic outcome. Efforts have been made to develop relevant and efficient non-invasive methods to assess the presence and the extent of tumor hypoxia in patients but have met little success. The ability to quantify tissue hypoxia will allow the physicians to select patients for additional or alternative treatment regimens that would circumvent the ominous impact of hypoxia [18]. Metronidazole (MN), a 5-nitroimidazole analogue, was shown to sensitize only anoxic cells in a dose dependent manner, a maximum enhancement ratio of 1.9 being obtained (2.5 for MISO) [69]. EC-MN was then synthesized and the structure is shown in (Fig. 5). The thymidine incorporation assay revealed that EC-MN is directly involved in the cell nuclei activity whereas MN showed less involvement in nuclei activity, (Fig. 6A). There were similar cellular uptakes (2-10%) between $^{99m}$Tc- and $^{68}$Ga-EC-MN at 0.5-4 hrs shown in (Figs. 6B-C and 6D) showed $^{68}$Ga-EC-MN exhibits
Assessment of Metabolic Imaging

There is a structural similarity between FDG and glucosamine. For instance, both agents have same configuration. FDG and glucosamine have fluorine and amino group at the position-2 of the sugar. Similarly to FDG, cellular uptake of glucosamine is via the glucose transporter process [16]. However, the regulatory products of glucosamine-6-phosphate mediate insulin activation, downstream signaling and translocation, which upregulate mRNA expression and tumor growth.

Our previous work demonstrated that tumor uptake of $^{99m}$Tc-EC-DG is via a glucose-mediated process [16,70]. One reason may be that the molecule (EC-DG) has multiple key structural position(s), such as positions 2 and 6 for D-glucosamine and the two COO- arms and two thiol (SH) locations for EC. During synthesis, the molecule changes via a peptide-linkage between the 2 position of the sugar with EC and occurs at both carboxy groups of EC. EC forms a peptide bond linkage with 2 thiols which can react with glycoproteins in the lumen of the cell membrane, such as O-linked N-acetylgalactosamine [71-74]. It is likely that SH bonds of EC-DG bind to cytosolic and transmembrane enzymes (Beta-N-acetylgalactosaminidase and O-GlcNAc transferase) or membrane associated proteins (O-linked N-acetylgalactosamine) which form (EC-DG) S-S (protein) linkages and support the translocation of EC-DG into the cell nucleus. It is known that glucosamine is phosphorylated at positions 1 and 6 and binds with uridine diphospho-N-acetylglucosamine to form O-linked N-acetylgalactosamine at those same positions, which involves interaction between nuclear and cytosolic proteins. Recent studies demonstrate a role for O-GlcNAcylation in processes as diverse as transcription in the nucleus and signaling in the cytoplasm, suggesting that O-GlcNAc has both protein and site-specific influences on biochemistry and metabolism throughout the cell [71,72]. We believe that it is this mechanism that is occurring which makes EC-DG so unique in its ability to be internalized by the cell. The possible mechanism is shown in (Fig. 7).

![Fig. 6](image-url)
CONCLUSIONS

Noninvasive imaging assessment of tumor cell proliferation could be helpful in the evaluation of tumor growth potential, the degree of malignancy, and could provide an early assessment of treatment response prior to changes in tumor size determined by computed tomography (CT), magnetic resonance imaging (MRI), or ultrasonography. Understanding of tumor proliferative activity, in turn,
could aid in the selection of optimal therapy by estimating patient prognosis and selecting the proper management. Aiming to develop new radiolabeled ligands for metabolic imaging of tumors, a series of new ligands have been developed for PET and SPECT imaging of neoplasms. For apoptosis assessment, radiolabeled EC-annexin V showed the potential to predict early treatment response. For DNA/RNA markers, EC-Guan showed promising results in differentiating inflammation versus tumor. For angiogenesis imaging, EC-endostatin, EC-CBX and EC-C225 are adequate to assess specific targets. For tumor hypoxia imaging, a classic nitroimidazole agent such as metronidazole is useful to monitor treatment response and may have potential in drug resistance or radioresistance imaging. Our metabolic imaging agent, radiolabeled EC-DEG could assess tumor growth. All of these functional ligands should provide information for prediction or monitoring treatment response of tumors. Thus, they may improve the diagnosis, planning and monitoring of cancer treatment.

REFERENCES


